Abstract:Background: Haematological patients with severe thrombocytopenia and high thrombotic risk face challenges related to balancing bleeding and thrombosis risks. This study investigated factors associated with bleeding and thrombosis in high-risk haematological oncology patients with severe thrombocytopenia not receiving anticoagulant therapy and characterized their clinical features when both events occurred. Methods: A total of 446 haematological oncology patients with Caprini scores ≥ 5 were included from July 2022 to June 2023 at Mianyang City Central Hospital. Those not receiving prophylactic anticoagulants due to an admission platelet count < 50 × 109/L were studied. Patients were categorized into bleeding/nonbleeding and thrombotic/nonthrombotic groups on the basis of hospital course. Relevant clinical data were collected, and univariate/multivariate logistic regression was used to analyse the influencing factors. The platelet count at admission was assessed via ROC curves for thrombosis prediction. Results: In the bleeding group, higher proportions of patients with leukaemia, myeloid tumours, lung infections, and a central venous catheter (CVC) with two lumens were observed, along with shorter catheter durations, lower initial and minimum platelet counts during hospitalization, and prolonged plasminogen times (all P < 0.05). The thrombotic group had a greater thrombosis history, initial platelet count, use of two venous catheter lumens, parenteral nutrition, sedation, and autologous haematopoietic stem cell transplantation (Auto-HSCT), with a lower leukaemia proportion (P < 0.05). Logistic regression identified lymphoma type and minimum platelet count as bleeding protective factors and the Charlson Comorbidity Index (CCI) score as an independent risk factor. Thrombosis history, two venous catheter lumens, and sedation were risk factors for thrombosis. The median platelet count was lower at bleeding and thrombosis than at admission (P = 0.007). The platelet count at admission had predictive value for thrombosis, especially severe thrombocytopenia, with an AUC of 0.735 (95% CI 0.613-0.858, P = 0.003) and a cut-off value of 42.5 × 109/L. Conclusions: For haematological neoplasm patients with a high risk of venous thromboembolism (VTE), severe thrombocytopenia and high CCI scores, risk prevention and control of bleeding take precedence over thrombosis prophylaxis. Prophylactic anticoagulation is still recommended for patients with lymphoma assessed at high risk for VTE and with platelet counts of at least 42.5 × 109/L.

Optimizing central venous access devices insertion in thrombocytopenic patients: Balancing efficacy and safety

International experts consensus on optimal central vascular access device selection and management for patients with cancer

Systematic Review of the Safety and Efficacy of Central Vascular Access Device Securement

Central venous access device adverse events in pediatric patients with cancer: a systematic review and meta-analysis

Catheter-related complications in onco-hematologic children: A retrospective clinical study on 227 central venous access devices

Efficacy and safety of peripherally inserted central venous catheters in acute cardiac care management

Current Practice in Central Venous Catheterization

Safety of Mechanical Thrombectomy for Acute Ischemic Stroke in Patients with Thrombocytopenia

Feasibility and efficacy of real-time ultrasound-guided venous closure with suture-mediated vascular closure device

Central venous catheters-related-thrombosis and risk factors in oncological patients: A retrospective evaluation of recent risk scores

Challenges in using central venous access devices outside of ICU settings in pediatrics

Daily point-of-care ultrasound-assessment of central venous catheter-related thrombosis in critically ill patients: a prospective multicenter study

Clinical analysis of bleeding and thrombotic events in haematological-oncology patients with severe thrombocytopenia and a high risk of thrombosis

Feasibility of totally implantable venous access ports in the upper arm for patients with head and neck cancer in the modern era of chemotherapy

A Retrospective Cohort Study of Implantable Venous Access Port-Related and Peripherally Inserted Central Catheter-Related Complications in Patients with Hematological Malignancies in China

No contraindication to internal jugular central venous catheter insertion in patients at increased risk of bleeding: Results from a prospective observational study in a internal medicine department

Central Venous Catheter Complications in the Poisoning Emergency Center: A 5-Year Cross-Sectional Study

The development of a nurse-driven protocol for the safe administration of vasopressors through peripheral intravenous catheters

Complications of central venous access devices in paediatric haemophilia patients

Risk Factors for Central Venous Access Device-Related Thrombosis in Hospitalized Children: A Systematic Review and Meta-Analysis

Compare the efficacy of recommended peripheral intravascular cannula insertion practices with a standard protocol: A randomized control trial